Navigation Links
Vical Announces News Release and Conference Call Schedule for 2007 Financial Results
Date:2/14/2008

SAN DIEGO, Feb. 14 /PRNewswire-FirstCall/ -- Vical Incorporated (Nasdaq: VICL) today announced that the company will report financial results for the quarter and year ended December 31, 2007, before the opening of trading on Thursday, February 21, and conduct a conference call and webcast to discuss the financial results and provide a company update at noon Eastern Time on Thursday, February 21. The call is open on a listen-only basis to any interested parties. The company will provide details on independent and partnered development programs in the conference call and webcast.

To listen to the conference call, dial in approximately ten minutes before the scheduled call to (888) 600-4883, or (913) 312-6683 for international participants, and reference confirmation code 5814630. A replay of the call will be available for 48 hours beginning about two hours after the call. To listen to the replay, dial (888) 203-1112, or (719) 457-0820 for international participants, and enter replay passcode 5814630. The call also will be available live and archived through the events page at http://www.vical.com.

Invited analysts and institutional investors may ask questions during the conference call. Others may submit questions before the call by e-mail addressed to info@vical.com or by fax to (858) 646-1150. Submitted questions will be screened for appropriateness and general interest. Selected questions received with sufficient notice before the call will be answered as time permits at the end of the call. For further information, contact Vical's Investor Relations department by phone at (858) 646-1127 or by e-mail at info@vical.com.

About Vical

Vical researches and develops biopharmaceutical products based on its patented DNA delivery technologies for the prevention and treatment of serious or life-threatening diseases. Potential applications of the company's DNA delivery technology include DNA vaccines for infectious diseases or cancer, in which the expressed protein is an immunogen; cancer immunotherapeutics, in which the expressed protein is an immune system stimulant; and cardiovascular therapies, in which the expressed protein is an angiogenic growth factor. The company is developing certain infectious disease vaccines and cancer therapeutics internally. In addition, the company collaborates with major pharmaceutical companies and biotechnology companies that give it access to complementary technologies or greater resources. These strategic partnerships provide the company with mutually beneficial opportunities to expand its product pipeline and address significant unmet medical needs. Additional information on Vical is available at http://www.vical.com.

This press release contains forward-looking statements subject to risks and uncertainties that could cause actual results to differ materially from those projected. Forward-looking statements include statements about the company's focus, collaborative partners, product candidates, and developmental status. Risks and uncertainties include whether any product candidates will be shown to be safe and efficacious in clinical trials, the timing of clinical trials, whether Vical or its collaborative partners will seek or gain approval to market any product candidates, the dependence of the company on its collaborative partners, and additional risks set forth in the company's filings with the Securities and Exchange Commission. These forward-looking statements represent the company's judgment as of the date of this release. The company disclaims, however, any intent or obligation to update these forward-looking statements.

Contact: Alan R. Engbring

(858) 646-1127

Website: http://www.vical.com


'/>"/>
SOURCE Vical Incorporated
Copyright©2008 PR Newswire.
All rights reserved

Related medicine news :

1. Vical to Present at BIO CEO and Investor Conference
2. Hollywood On the Hill - A Red Carpet Event on Capitol Hill Raises Awareness for Cervical Cancer Prevention and HPV-Related Technologies
3. National Cervical Cancer Coalition (NCCC) State Chapters to Provide Parents With Educational Forum to Discuss Cervical Cancer and HPV Vaccines
4. Independence Blue Cross Delivers Important Reminder to Women during Cervical Cancer Awareness Month
5. National Cervical Cancer Coalition Stresses Importance of Screening and Prevention During January Cervical Health Awareness Month
6. Study determines costs of breast and cervical cancer detection among low-income women
7. GlaxoSmithKline Receives FDA Complete Response Letter for Cervical Cancer Vaccine
8. Vical Expands Clinical Testing of DNA Vaccine Against H5N1 Pandemic Influenza
9. Post-treatment PET scans can reassure cervical cancer patients
10. PET Scans Can Spot Cervical Cancers Return
11. Pill Poses Little Cervical Cancer Risk
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:3/29/2017)... ... , ... Hamlin Dental Group, multi-location dental office in North Hollywood , ... are safe and effective options, and can be used alone or in conjunction with ... of care. , Dr. Hamid Reza of Hamlin Dental Group offers other treatments as ...
(Date:3/29/2017)... ... March 29, 2017 , ... Physicians’ Education ... specialized continuing medical education conference for clinicians who manage some of the most ... York. , The program will be led by co- chairs Dr. John ...
(Date:3/29/2017)... , ... March 29, 2017 , ... AvePoint , ... North American office location in Richmond, Virginia, located at the Riverfront Plaza, 901 East ... by Lieutenant Governor of Virginia Ralph S. Northam and Mayor of Richmond Levar M. ...
(Date:3/28/2017)... Boulder, CO (PRWEB) , ... March 28, 2017 ... ... the reasonable assumption that in order to improve teacher quality, the field must ... “blindly swinging from one popular reform to the next” and that decades of ...
(Date:3/28/2017)... (PRWEB) , ... March 28, 2017 , ... For many women, getting birth control isn’t ... deserts , meaning they either don’t have access to a health care facility or a ... and remote regions of the United States or for many who are faced with health ...
Breaking Medicine News(10 mins):
(Date:3/29/2017)... Research and Markets has announced the addition of the ... to their offering. ... The ablation device global market is expected to grow at ... Ablation is the minimally invasive therapeutic tissue excision procedure ... tissue removal, to the removal of abnormally conducting cardiac tissue in ...
(Date:3/29/2017)... , March 29, 2017   Dynatronics Corporation ... the appointment of Cynthia L. McHenry ... be responsible for leading Dynatronics manufacturing, distribution, and ... report to Dynatronics, CEO Kelvyn H. Cullimore, ... an extensive search process conducted by the company ...
(Date:3/29/2017)... , March 29, 2017 FinancialBuzz.com News Commentary  ... Data published in a research ... market will reach a value of USD 55.8 billion by 2025. The ... the United States and a more open approach towards cannabis ... , Florida , North Dakota , ...
Breaking Medicine Technology: